Biomotion Sciences Ordina... (SLXN)
1.79
-0.06 (-3.24%)
At close: Jan 14, 2025, 3:59 PM
1.77
-1.12%
Pre-market Jan 15, 2025, 07:24 AM EST
undefined% (undefined)
| Bid | 1.75 |
| Market Cap | 2.87M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.22 |
| PE Ratio (ttm) | -0.14 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.85 |
| Volume | 248,607 |
| Avg. Volume (20D) | 4,511,019 |
| Open | 1.86 |
| Previous Close | 1.85 |
| Day's Range | 1.76 - 1.94 |
| 52-Week Range | 0.21 - 13.56 |
| Beta | undefined |
About SLXN
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol SLXN
Website https://silexion.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 402.79% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+47.06%
Silexion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago ·
Source
+5.92%
Silexion Therapeutics shares are trading higher after the company announced new preclinical findings for SIL-204.
